Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 419.3Cr 366.43Cr 344.39Cr 314.28Cr 589.85Cr 40TCr 589.96Cr 4.13TCr 1.59TCr 20TCr 1.57TCr 1.54TCr 66TCr P/E 2026 *
9.55x
P/E 2027 * 8.66x
Enterprise Value 418.05Cr 365.34Cr 343.37Cr 313.34Cr 588.09Cr 40TCr 588.2Cr 4.12TCr 1.59TCr 20TCr 1.57TCr 1.54TCr 66TCr EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.59x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day+1.89%
1 week+6.41%
Current month+4.25%
1 month+0.65%
3 months-4.97%
6 months+23.90%
Current year+1.49%
1 week 33.84
Extreme 33.84
36.63
1 month 33.74
Extreme 33.74
36.82
Current year 27.68
Extreme 27.68
42.81
1 year 22.56
Extreme 22.555
42.81
3 years 7.33
Extreme 7.33
42.81
5 years 7.33
Extreme 7.33
42.81
10 years 1.75
Extreme 1.75
42.81
Date Insider Type Main position Quantity % Market Cap. Importance
27/08/26 Buy

Controller/Auditor

1,500 0.0012%
05/08/26 Buy

Controller/Auditor

1,500 0.0012%
10/07/26 Sell

Chief Scientific Officer

-18,586 0.0152%
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%+6.41%+56.49%+63.37% 419.3Cr
+0.83%+3.13%+55.20%+112.82% 1,03800Cr
+0.13%+0.87%+54.72%+67.93% 65TCr
+0.57%+1.03%+19.39%+73.99% 47TCr
-0.19%+0.97%+34.30%+45.99% 36TCr
+0.28%+2.30%+18.47%+26.67% 27TCr
+0.89%+4.59%+10.19%+14.72% 26TCr
+4.42%+9.08%+43.27%+53.06% 21TCr
-0.46%-6.20%-32.46%-59.65% 18TCr
+1.46%+4.37%+35.74%+103.57% 19TCr
Average +0.97%+2.00%+29.53%+50.25% 36.19TCr
Weighted average by Cap. +0.71%+1.90%+36.50%+67.29%

Financials

2026 *2027 *
Net sales 133.2Cr 116.4Cr 109.4Cr 100Cr 187.37Cr 13TCr 187.41Cr 1.31TCr 506.65Cr 6.5TCr 500.21Cr 489.24Cr 21TCr 139.95Cr 122.31Cr 114.95Cr 104.9Cr 196.88Cr 13TCr 196.91Cr 1.38TCr 532.35Cr 6.83TCr 525.58Cr 514.06Cr 22TCr
Net income 47Cr 41Cr 39Cr 36Cr 67Cr 4.53TCr 67Cr 467.51Cr 180.4Cr 2.32TCr 178.11Cr 174.2Cr 7.46TCr 53Cr 46Cr 44Cr 40Cr 75Cr 5.07TCr 75Cr 522.42Cr 201.59Cr 2.59TCr 199.02Cr 194.66Cr 8.34TCr
Net Debt -1.25Cr -1.09Cr -1.03Cr -93.69L -1.76Cr -119.5Cr -1.76Cr -12Cr -4.75Cr -61Cr -4.69Cr -4.59Cr -196.73Cr -57Cr -50Cr -47Cr -43Cr -80Cr -5.45TCr -80Cr -561.88Cr -216.82Cr -2.78TCr -214.06Cr -209.37Cr -8.97TCr
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
23/26/23 $36.19 +1.86% 16,41,650
21/26/21 $35.53 +1.86% 12,98,962
18/26/18 $34.88 -2.27% 46,84,180
17/26/17 $35.69 +3.90% 26,90,502
16/26/16 $34.35 +0.38% 18,65,882
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
35.53USD
Average target price
49.00USD
Spread / Average Target
+37.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INDV Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!